Pharsight

Tuxarin Er patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9066942 MAINPOINTE Oral dosage forms for oxygen-containing active agents and oxyl-containing polymer
Jan, 2032

(7 years from now)

US9107921 MAINPOINTE Oral dosage forms for oxygen containing active agents and oxyl-containing polymers
Jan, 2032

(7 years from now)

Tuxarin Er is owned by Mainpointe.

Tuxarin Er contains Chlorpheniramine Maleate; Codeine Phosphate.

Tuxarin Er has a total of 2 drug patents out of which 0 drug patents have expired.

Tuxarin Er was authorised for market use on 22 June, 2015.

Tuxarin Er is available in tablet, extended release;oral dosage forms.

Tuxarin Er can be used as treatment of cough and symptoms associated with upper respiratory allergies or a common cold with codeine phosphate and chlorpheniramine maleate orally administered extended release tablets.

The generics of Tuxarin Er are possible to be released after 03 January, 2032.

Drugs and Companies using CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE ingredient

Market Authorisation Date: 22 June, 2015

Treatment: Treatment of cough and symptoms associated with upper respiratory allergies or a common cold with codeine phosphate and chlorpheniramine maleate orally administered extended release tablets

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

TUXARIN ER family patents

Family Patents